Increase in Blood Levels of Growth Factors Involved in the Neuroplasticity Process by Using an Extremely Low Frequency Electromagnetic Field in Post-stroke Patients

Cichoń, Natalia; Bijak, Michał; Czarny, Piotr; Miller, Elżbieta; Synowiec, Ewelina; Śliwiński, Tomasz; Saluk‐Bijak, Joanna

doi:10.3389/fnagi.2018.00294

Cited by 30 publications

(22 citation statements)

References 62 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The crucial role of BDNF in neuroplasticity was primarily revealed by studies that focused on the poststroke treatment of aphasia and lost motor function, which are largely 5 Neural Plasticity mediated by the process of neuroplasticity [77,78]. In previous studies using rat ischemia models, it was found that when BDNF synthesis was blocked, the beneficial effects on the recovery of skilled reaching were mostly negated [79], while intravenous administration of BDNF significantly enhanced the functional motor recovery of the treated rats, compared to the untreated controls [80,81].…”

Section: Bdnf Induces Neuroplasticity In Poststroke Rehabilitationmentioning

confidence: 99%

Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities

et al. 2020

View full text Add to dashboard Cite

With the rise in the aging global population, stroke comorbidities have become a serious health threat and a tremendous economic burden on human society. Current therapeutic strategies mainly focus on protecting neurons from cytotoxic damage at the acute phase upon stroke onset, which not only is a difficult way to ameliorate stroke symptoms but also presents a challenge for the patients to receive effective treatment in time. The brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the adult brain, which possesses a remarkable capability to repair brain damage. Recent promising preclinical outcomes have made BDNF a popular late-stage target in the development of novel stroke treatments. In this review, we aim to summarize the latest progress in the understanding of the cellular/molecular mechanisms underlying stroke pathogenesis, current strategies and difficulties in drug development, the mechanism of BDNF action in poststroke neurorehabilitation and neuroplasticity, and recent updates in novel therapeutic methods.

show abstract

Section: Bdnf Induces Neuroplasticity In Poststroke Rehabilitationmentioning

confidence: 99%

Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Another promising form of magnetic field application in the treatment of patients after stroke is extremely lowfrequency electromagnetic field therapy (ELF-EMF). Research shows that the use of EL-EMF may enhance neuroplasticity and functional recovery after stroke by increasing nitric oxide generation and its metabolism, which have both neuroprotective and cytotoxic properties [119], as well as by increasing BDNF concentration [120].…”

Section: Magnetic Fieldmentioning

confidence: 99%

Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery

Szelenberger

Kostka

Saluk‐Bijak

et al. 2019

Self Cite

View full text Add to dashboard Cite

Neuroplasticity is a natural process occurring in the brain for the entire life. Stroke is the leading cause of long term disability and a huge medical and financial problem throughout the world. Research conducted over the past decade focused mainly on neuroprotection in the acute phase of stroke while very little studies target the chronic stage. Recovery after stroke depends on the ability of our brain to reestablish the structural and functional organization of neurovascular networks. Combining adjuvant therapies and drugs may enhance the repair processes and restore impaired brain functions. Currently, there are some drugs and rehabilitative strategies that can facilitate brain repair and improve clinical effect even years after stroke onset. Moreover, some of the compounds such as citicoline, fluoxetine, niacin, levodopa, etc. are already in clinical use or are being trialed in clinical issues. Many studies are also testing cell therapies; in our review, we focused on studies where cells have been implemented at the early stage of stroke. Next, we discuss pharmaceutical interventions. In this section, we selected methods of cognitive, behavioral, and physical rehabilitation as well as adjuvant interventions for neuroprotection including noninvasive brain stimulation and extremely low-frequency electromagnetic field. The modern rehabilitation represents a new model of physical interventions with the limited therapeutic window up to six months after stroke. However, previous studies suggest that the time window for stroke recovery is much longer than previously thought. This review attempts to present the progress in neuroprotective strategies, both pharmacological and non-pharmacological that can stimulate the endogenous neuroplasticity in post-stroke patients.

show abstract

“…After a four-week rehabilitation program where one group also received ELF-EMF field (40 Hz, 7 mT for 15 min/day for four weeks), ELF-EMF induced a significant improvement in functional (Activities of Daily Living) and mental (Mini-Mental State Examination and Geriatric Depression Scale) status. As well as an increase in antioxidant gene expression, nitric oxide metabolites, oxidative stress, and interleukin-1β were all improved/increased [37][38][39][40][41][42]. Indeed, a neuroprotective role of IL-1β-dependent in the regulation of neurotrophic factors has already been hypothesized [43].…”

Section: Discussionmentioning

confidence: 95%

Pilot Study on the Effect of Biophysical Therapy on Salivary Alpha-Amylase as a Surrogate Measure of Anxiety/Stress: In Search of a Novel Noninvasive Molecular Approach for the Management of Stress

Ferrara

Egan²,

Foletti

2020

IJMS

View full text Add to dashboard Cite

Anxiety and depression impact dramatically on public health, underlying the importance of alternative cost-effective treatments. Previous studies have shown that biophysical treatment can significantly reduce anxiety symptoms and recently, salivary alpha-amylase (SAA) has been identified as an objective correlate of the sympathetic-parasympathetic imbalance related to increased stress burden, defined as allostatic load. The aim of this study was to evaluate the effect of biophysical therapy on SAA levels, in addition to the Depression Anxiety Stress Scale (DASS)-21 questionnaire. Twenty-four workers (sales representatives) presenting with mild anxiety/stress symptoms (Generalized Anxiety Disorder 7-item scale of > 5) were randomized to biophysical treatment (N = 12) or placebo control (N = 12). The biophysical group underwent electromagnetic information transfer through an aqueous system procedure, with daily self-administration for one month. SAA collection and the DASS-21 questionnaire were undertaken at baseline and after one month in all patients. Clinical characteristics and baseline DASS-21 subscale scores were similar between placebo and biophysical group at baseline. After one month, patients receiving biophysical therapy had significantly reduced SAA levels compared to the placebo group (27.8 ± 39.4 vs. 116.8 ± 114.9 U/mL, p = 0.019). All three DASS-21 subscales, depression (9.3 ± 5.1 vs. 5.7 ± 5.5, p = 0.1), anxiety (6.7 ± 25 vs. 3.7 ± 2.2, p = 0.0049) and stress (10.8 ± 4.2 vs. 7.3 ± 3.7, p = 0.041) were also decreased after biophysical treatment compared to placebo after one month. Our findings suggest that biophysical therapy can benefit workers with mild (subclinical) anxiety/stress. These results were also validated by the concomitant reduction of SAA levels and an improvement in DASS-21 subscales. The underlying molecular mechanisms of this therapy remain to be characterized.

show abstract

Increase in Blood Levels of Growth Factors Involved in the Neuroplasticity Process by Using an Extremely Low Frequency Electromagnetic Field in Post-stroke Patients

Cited by 30 publications

References 62 publications

Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities

Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities

Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery

Pilot Study on the Effect of Biophysical Therapy on Salivary Alpha-Amylase as a Surrogate Measure of Anxiety/Stress: In Search of a Novel Noninvasive Molecular Approach for the Management of Stress

Contact Info

Product

Resources

About